FLT3 and leukemia: The CLSG/GCEL panel believes that at present, most leukemia centers in Canada perform upfront PCR-fragment analysis for FLT3-ITD detection (to take advantage of the fast turnaround time) and perform NGS to identify other clinically relevant mutations.